AstraZeneca: Respiratory Syncytial Virus Infections trials

The registry lists 14 Respiratory Syncytial Virus Infections studies with AstraZeneca as lead sponsor. 0 are open to participants now and 10 have results posted.

Phase 1 5Phase 2 5Phase 3 4No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess Safety, Pharmacokinetics Anti-Drug Antibody and Anti-RSV Antibody After 2 Doses of NirsevimabCompletedNCT06042049Phase 3Results posted
• Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised ChildrenCompletedNCT04484935Phase 2Results posted
• A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)CompletedNCT03979313Phase 3Results posted
• A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk ChildrenCompletedNCT03959488Phase 2/3Results posted
• A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants.CompletedNCT02878330Phase 2Results posted
• A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy AdultsCompletedNCT02114268Phase 1Results posted
• Intranasal Challenge of Healthy Adults With Respiratory Syncytial Virus (RSV)TerminatedNCT01475305Phase 1Results posted
• Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of AgeCompletedNCT00493285Phase 1Results posted
• Study of Motavizumab (MEDI-524) and Palivizumab Administered Sequentially in the Same Respiratory Syncytial Virus (RSV) SeasonCompletedNCT00316264Phase 2Results posted
• Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk ChildrenCompletedNCT00129766Phase 3Results posted
• Study to Evaluate the Incidence of Hospitalizations and Respiratory Tract Infections in Premature InfantsCompletedNCT00384462
• Open-Label, Dose-Escalation Study of 2 to 5 IM Doses of MEDI-524 at 3 mg/kg or 15 mg/kg; Children to be Followed for 90 Days After Their Last Dose of MEDI-524CompletedNCT00192478Phase 1/2
• Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 in Healthy AdultsCompletedNCT00192465Phase 1
• Study to Evaluate MEDI-534 in Healthy AdultsCompletedNCT00111878